Fagron

Fagron FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Fagron (FAGR.BR) as of Oct 10, 2026 is 124.18 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 103.86 % — a change of 19.57% (higher).

FCF Conversion

124.18 %

YoY

19.57%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Fagron is 2025 124.18 % . FCF Conversion Rate (FCF/EBITDA) of Fagron was 2024 103.86 % . It decreases by 19.57% higher compared to the previous year.

The Fagron FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
135.54 EUR
Jan 1, 2019
98.77 EUR
Jan 1, 2020
125.05 EUR
Jan 1, 2021
94.56 EUR
Jan 1, 2022
130.67 EUR
Jan 1, 2023
97.67 EUR
Jan 1, 2024
103.86 EUR
Jan 1, 2025
124.18 EUR
The Fagron FCF Conversion history
YEARFCF ConversionYoY
124.18 %+19.57%
103.86 %+6.33%
97.67 %-25.25%
130.67 %+38.18%
94.56 %-24.38%
125.05 %+26.61%
98.77 %-27.13%
135.54 %-14.79%
159.06 %-162.03%
-256.43 %+912.17%
-25.33 %-105.07%
499.45 %—
Access this data via the Eulerpool API

Fagron Stock analysis

What does Fagron do? Fagron NV is an internationally operating company that focuses on the development and production of customized medications for pharmacies and hospitals. The company was founded in 1990 in Rotterdam, Netherlands. The beginnings of Fagron NV were in the Netherlands, where the company was established as Roterodamum Chemie BV. In the late 1990s, the company was converted into a holding company called Arseus NV, which later received the name Fagron. In 2012, Fagron was listed on the Euronext stock exchange in Brussels. Fagron operates globally and has locations in Europe, North America, Latin America, the United Arab Emirates, Asia, and Australia. Fagron's business model is based on the production of specialized medications for individual patient needs. The company offers a wide range of pharmaceutical active ingredients, raw materials, and processing services. There is also the possibility to develop and manufacture customized formulations tailored to the needs of patients. Fagron not only manufactures customized medications but also provides training and support for pharmacies and hospitals. Fagron operates in three main divisions: Specialty Pharma (hospital care), Community Pharma (prescription and non-prescription medications), and Compounding Services (custom formulations). The Specialty Pharma division specializes in medications for use in hospitals. It offers a wide range of products that can be used in the treatment of conditions such as cancer, HIV, and tuberculosis. These medications are manufactured in various dosage forms, such as injections, infusions, and tablets. The Community Pharma division focuses on prescription and non-prescription medications. Both branded and generic medications are offered. These are delivered directly to pharmacies, hospitals, and clinics. The Compounding Services division specializes in the production of customized medications. Fagron works closely with pharmacies and hospitals to meet individual needs. This includes, for example, the manufacture of medications in specific dosages or the combination of several active ingredients in a custom formulation. Fagron offers a wide range of products, including hormones, pain medications, cancer drugs, medications for the treatment of skin diseases, ophthalmic products, and anti-infectives. Pharmaceutical active ingredients and raw materials are also offered. Overall, Fagron is a global leader in the production of customized medications. It has extensive experience and expertise in the manufacturing of pharmaceutical formulations and offers a wide range of products and services. The various divisions of Fagron allow the company to meet the diverse needs of its customers and maintain its position as a leading company in the pharmaceutical industry. Fagron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fagron stock

FCF Conversion Rate (FCF/EBITDA) of Fagron is 124.18 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Fagron changed from 103.86 % to 124.18 %, representing a 19.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Fagron since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Fagron with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Fagron

All Key Metrics — Fagron